5α-reductase type 3 enzyme in benign and malignant prostate

Prostate

Volumn 74, Issue 3, 2014, Pages 235-249

  Titus, Mark A ^a   Li, Yun ^a   Kozyreva, Olga G ^c   Maher, Varun ^a   Godoy, Alejandro ^a   Smith, Gary J ^a   Mohler, James L ^a,b,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

5 reductase; androgen metabolism; benign prostatic hyperplasia; castration recurrent prostate cancer; dihydrotestosterone

Indexed keywords

5ALPHA PREGNANE 3,20 DIONE; 5ALPHA REDUCTASE TYPE 3; ABIRATERONE; ANDROGEN; ANDROSTANEDIONE; ANDROSTANOLONE; ANDROSTENEDIONE; DUTASTERIDE; MESSENGER RNA; PROGESTERONE; RECOMBINANT ENZYME; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; TESTOSTERONE; UNCLASSIFIED DRUG;

ANDROGEN METABOLISM; ANIMAL CELL; ARTICLE; BIOTRANSFORMATION; CASTRATION RESISTANT PROSTATE CANCER; CELL LYSATE; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MALE; METABOLITE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; TANDEM MASS SPECTROMETRY; THIN LAYER CHROMATOGRAPHY;

EID: 84892446077     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22745     Document Type: Article

References (51)

1. Wilson JD,. The role of 5alpha-reduction in steroid hormone physiology. Reprod Fertil Dev 2001; 13 (7-8): 673-678.
2. Frye SV,. Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor. Curr Top Med Chem 2006; 6 (5): 405-421.
3. Gormley GJ, Stoner E, Rittmaster RS, Gregg H, Thompson DL, Lasseter KC, Vlasses PH, Stein EA,. Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab 1990; 70 (4): 1136-1141.
4. Span PN, Voller MC, Smals AG, Sweep FG, Schalken JA, Feneley MR, Kirby RS,. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. J Urol 1999; 161 (1): 332-337.
5. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S,. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004. 89 (5): 2179-2184.
6. Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R,. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology 2008; 72 (4): 808-812.
7. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CAJ,. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349 (3): 215-224.
8. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS,. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362 (13): 1192-1202.
9. Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, Lazier CB, Rittmaster RS,. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004; 172 (3): 915-919.
10. Walsh PC,. Chemoprevention of prostate cancer. N Engl J Med 2010; 362 (13): 1237-1238.
11. Andriole G, Lieber M, Smith J, Soloway M, Schroeder F, Kadmon D, DeKernion J, Rajfer J, Boake R, Crawford D, Ramsey E, Perreault J, Trachtenberg J, Fradet Y, Block N, Middelton R, Ng J, Ferguson D, Gormley G,. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 1995; 45 (3): 491-497.
12. Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL,. Phase II study of dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol 2009. 181 (2): 621-626.
13. Lamb JC, Levy MA, Johnson RK, Isaacs JT,. Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK&F 105657. Prostate 1992; 21 (1): 15-34.
14. Schmidt LJ, Regan KM, Anderson SK, Sun Z, Ballman KV, Tindall DJ,. Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts. Prostate 2009; 69 (16): 1730-1743.
15. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT,. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 2006; 12 (13): 4072-4079.
16. Mahendroo MS, Cala KM, Hess DL, Russell DW,. Unexpected virilization in male mice lacking steroid 5 alpha-reductase enzymes. Endocrinology 2001; 142 (11): 4652-4662.
17. Godoy A, Kawinski E, Li Y, Oka D, Alexiev B, Azzouni F, Titus MA, Mohler JL,. 5alpha-Reductase type 3 expression in human benign and malignant tissues: A comparative analysis during prostate cancer progression. Prostate 2011; 71 (10): 1033-1046.
18. Thigpen AE, Cala KM, Russell DW,. Characterization of Chinese hamster ovary cell lines expressing human steroid 5 alpha-reductase isozymes. J Biol Chem 1993; 268 (23): 17404-17412.
19. Titus MA, Gregory CW, Ford OHr, Schell MJ, Maygarden SJ, Mohler JL,. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005; 11 (12): 4365-4371.
20. Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R,. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2007; 10 (2): 149-154.
21. Godin C, Provost PR, Poirier D, Blomquist CH, Tremblay Y,. Separation by thin-layer chromatography of the most common androgen-derived C19 steroids formed by mammalian cells. Steroids 1999; 64 (11): 767-769.
22. Lih FB, Titus MA, Mohler JL, Tomer KB,. Atmospheric pressure photoionization tandem mass spectrometry of androgens in prostate cancer. Anal Chem 2010; 82 (14): 6000-6007.
23. Morrison C, Cheney R, Johnson CS, Smith G, Mohler JL,. Central quadrant procurement of radical prostatectomy specimens. Prostate 2009; 69 (7): 770-773.
24. Epstein JI,. Evaluation of radical prostatectomy capsular margins of resection. The significance of margins designated as negative, closely approaching, and positive. Am J Surg Pathol 1990; 14 (7): 626-632.
25. Samson M, Labrie F, Luu-The V,. Sequential transformation of 4-androstenedione into dihydrotestosterone in prostate carcinoma (DU-145) cells indicates that 4-androstenedione and not testosterone is the substrate of 5alpha-reductase. Horm Mol Biol Clin Invest 2010; 1 (2): 67-72.
26. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, Sharifi N,. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci USA 2011; 108 (33): 13728-13733.
27. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC,. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68 (15): 6407-6415.
28. Dupuy GM, Roberts KD, Bleau G, Chapdelaine A,. Steroidal inhibitors of prostatic 5a-reductase: Structure activity relationship. J Steroid Biochem Mol Biol 1978; 9: 1043-1047.
29. Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, Oommen NB, Folkerd E, Dowsett M, Arlt W, de Bono JS,. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 2012; 97 (2): 507-516.
30. Auchus RJ,. The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 2004; 15 (9): 432-438.
31. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y, Nakagawa H,. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008; 99 (1): 81-86.
32. Langlois VS, Zhang D, Cooke GM, Trudeau VL,. Evolution of steroid-5alpha-reductases and comparison of their function with 5beta-reductase. Gen Comp Endocrinol 2010; 166 (3): 489-497.
33. Cantagrel V, Lefeber DJ, Ng BG, Guan Z, Silhavy JL, Bielas SL, Lehle L, Hombauer H, Adamowicz M, Swiezewska E, De Brouwer AP, Blumel P, Sykut-Cegielska J, Houliston S, Swistun D, Ali BR, Dobyns WB, Babovic-Vuksanovic D, van Bokhoven H, Wevers RA, Raetz CR, Freeze HH, Morava E, Al-Gazali L, Gleeson JG,. SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cell 2010; 142 (2): 203-217.
34. Gupta MK, Guryev OL, Auchus RJ,. 5alpha-reduced C21 steroids are substrates for human cytochrome P450c17. Arch Biochem Biophys 2003; 418 (2): 151-160.
35. Bauman DR, Steckelbroeck S, Williams MV, Peehl DM, Penning TM,. Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: A potential therapeutic target for androgen-dependent disease. Mol Endocrinol 2006; 20 (2): 444-458.
36. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS,. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 2008; 68 (11): 4447-4454.
37. Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, Fleisher M, Sander C, Sawyers CL, Scher HI,. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res 2012; 72 (23): 6142-6152.
38. Khersonsky O, Tawfik DS,. Enzyme promiscuity: A mechanistic and evolutionary perspective. Annu Rev Biochem 2010; 79: 471-505.
39. Tian G, Stuart JD, Moss ML, Domanico PL, Bramson HN, Patel IR, Kadwell SH, Overton LK, Kost TA, Mook RAJ, Frye SV, Batchelor KW, Wiseman JS,. 17 beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5 alpha-reductase 1. Biochemistry 1994; 33 (8): 2291-2296.
40. Tian G, Mook RAJ, Moss ML, Frye SV,. Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: Toward perfection of rates of time-dependent inhibition by using ligand-binding energies. Biochemistry 1995; 34 (41): 13453-13459.
41. Levy MA, Brandt M, Greway AT,. Mechanistic studies with solubilized rat liver steroid 5 alpha-reductase: Elucidation of the kinetic mechanism. Biochemistry 1990; 29 (11): 2808-2815.
42. Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O'Brien SP, Rittmaster RS,. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005; 63 (3): 231-239.
43. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB,. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinoma. Prostate 2003; 57 (2): 134-139.
44. Elo JP, Akinola LA, Poutanen M, Vihko P, Kyllonen AP, Lukkarinen O, Vihko R,. Characterization of 17beta-hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate. Int J Cancer 1996; 66 (1): 37-41.
45. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP,. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66 (5): 2815-2825.
46. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D, Breed S, Somerville M, Rittmaster R,. Chemoprevention of prostate cancer in men at high risk: Rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol 2004; 172 (4 Pt 1): 1314-1317.
47. Eisenberger MA, Laufer M, Vogelzang NJ, Sartor O, Thornton D, Neubauer BL, Sinibaldi V, Lieskovsky G, Carducci MA, Zahurak M, Raghavan D,. Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: Elevation of estradiol as possible mechanism of action. Urology 2004; 63 (1): 114-119.
48. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL,. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005; 11 (13): 4653-4657.
49. Mohler JL, Gregory CW, Ford OHr, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS,. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10 (2): 440-448.
50. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Moore M, Palackal N, Ratnam K,. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: Functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000; 351 (Pt 1): 67-77.
51. Mohler JL, Titus MA, Wilson EM,. Potential prostate cancer drug target: Bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res 2011; 17 (18): 5844-5849.